

## Highly Specialised Technology Committee [HST] Interests Register

**Topic: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma [ID6193]**

**Publication Date: 08/05/2024**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
<b>Stuart Mealing</b>	Committee Member	Financial interests	Other members of the company have done work for Sanofi in the same underlying disease, about four years ago.	10/01/2024	It was agreed that Stuart's declaration would not prevent him from participating in discussions on this appraisal.
<b>Emtiyaz Chowdhury</b>	Committee Member	Non-financial professional interests	Emtiyaz Chowdhury have provided access consulting services to Menarini over the last 12 months on behalf of my employer Parexel. The activities pertained to two technologies, Elzonris for patients with BPCDN and obicetrapic for patients with uncontrolled LDL levels. Menarini do not have any agreed services with Emtiyaz's team to provide support for the technology.	10/01/2024	It was agreed that Emtiyaz's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
<b>Dr Prithwiraj Das</b>	Committee Member	Non-financial professional interests	Prithwiraj Das works in life sciences, including pharmaceutical market access, as Founding Director of G2PR ltd. He have not worked on these products/indications in the last 12+ months.	10/01/2024	It was agreed that Dr Das' declaration would not prevent him from participating in discussions on this appraisal.
<b>Giles Monnickendam</b>	Committee Member	Financial interests	Giles Monnickendam has received honoraria and consulting fees received from Janssen with respect to talquetemab and cilta-cel in relapsed refractory multiple myeloma.	10/01/2024	It was agreed that Giles' declaration would not prevent him from participating in discussions on this appraisal.
<b>Michael Chambers</b>	Committee Member	Financial interests	Michael Chambers was an employee of GSK from 2006 to 2015, and do not retain any financial interest. He has provided consulting advice to Pfizer in unrelated disease areas (prostate cancer, COPD). Of these companies only GSK is participating in the appraisal.	10/01/2024	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
<b>Dr Neil Rabin</b>	Clinical Expert	Financial interest	Dr Neil Rabin has received support to attend conferences, speak at educational meetings and advisory boards for Celgene (BMS), Janssen-Cilag and Takeda. Furthermore, has received support to attend conference and advisory boards for Menirini-Stemline, to speak at educational meetings and advisory boards for Sanofi and to attend an advisory board for Amgen.	10/01/2024	It was agreed that Dr Rabin's declaration would not prevent him from providing expert advice to the committee.
<b>Dr Neil Rabin</b>	Clinical Expert	Non-financial professional and personal interest	Dr Neil Rabin is an executive member of the UK Myeloma Forum (provides education and advocates on behalf of myeloma doctors in the UK).	10/01/2024	It was agreed that Dr Rabin's declaration would not prevent him from providing expert advice to the committee
<b>Professor Karthik Ramasamy</b>	Clinical Expert	Non-financial professional and personal interest	Professor Karthik Ramasamy is an executive member of UK Myeloma society and Trustee for myeloma charity.	10/01/2024	It was agreed that Professor Ramasamy's declaration would not prevent him from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
<b>Professor Karthik Ramasamy</b>	Clinical Expert	Indirect interest	Professor Karthik Ramasamy has served as an advisor and has received speaker honoraria from AbbVie, Adaptive Biotechnologies, Amgen, Celgene (Bristol Myers Squibb), EUSA Pharma/ Recordati, Glaxo Smith Kline, Janssen, Karyopharm, Oncopeptides, Pfizer, Sanofi, and Takeda. Professor Ramasamy has also received conference Travel grants from Takeda, Janssen, Menarini Stemline	10/01/2024	It was agreed that Professor Ramasamy's declaration would not prevent him from providing expert advice to the committee